Industry Focus and Expertise

News

06.02.20
Excellere Partners Enters into Strategic Alliance Partnership with Amjed Saffarini, a Recognized Leader in Cybersecurity and Risk Management

Denver, CO, June 2, 2020 - Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, announced today that it has entered into a strategic alliance partnership with Amjed Saffarini, a proven leader in Cybersecurity services with a track record of success building, managing and growing technology driven product and service companies.

As an indication of its commitment to the Cybersecurity and Managed IT services market, Excellere joined forces with a reputable industry operator, Amjed Saffarini, to pursue a customer-centric investment effort focused on the rapidly growing Cybersecurity sector.  According to Justin Unertl, a Principal at Excellere, “Joining forces with Amjed allows us to broaden our investment considerations, efficiently evaluate opportunities, and provide immediate value to our new partners post-closing.  Amjed’s skilled and effective manner aligns perfectly with Excellere’s values-oriented approach to supporting talented entrepreneurs and executives.”

Mr. Saffarini brings over 20 years of experience as a CEO, board member and founder in cybersecurity, education and workforce development, most recently serving as the founder and CEO of CyberVista, a cybersecurity education company created to help solve the 2.5 million global worker shortage in cybersecurity by deploying the highest quality personalized online training programs available in the market.  Prior to CyberVista, he served as the President of Kaplan’s University Solutions Group, a division of Graham Holdings Company.  Amjed brings deep and relevant functional experience in product development, marketing and brand management, and strategic development capabilities to support Excellere’s investment interest in the cybersecurity sector.

“Cybersecurity is still a nascent industry where the playing field between malicious actors, governments, corporations and citizens is incredibly narrow,” said Saffarini.  “The ability to participate in the building of this exciting new discipline is exciting and comes around only once in a century.  I’m honored to be working with the Excellere team, who have shown the ability to help brilliant founder entrepreneurs in the past scale their ideas in similar societal impact markets like healthcare, critical infrastructure, and others.”

Brad Cornell, Partner at Excellere, added “Amjed’s experience in the cybersecurity sector makes him a valuable addition to Excellere’s Strategic Alliance Program.  With more of our time at the board level of our portfolio companies devoted to assessing and managing cybersecurity risks, we see a massive unmet need for quality IT, compliance and risk management providers to provide value to businesses of all sizes, particularly in the middle-market.

To learn more about Excellere’s interest in the Cybersecurity and Managed IT services sector, please contact Brad Cornell (303.765.2402), Justin Unertl (303.765.2416) or Ross Gundry (303.765.2372).

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital specializing in partnering with entrepreneurs and management teams. The firm employs a proven research-driven, top-down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth. Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends. Excellere’s targeted industry sectors include business services; healthcare services and products; industrial technology and specialty chemicals.  For more information about Excellere, please visit https://www.excellerepartners.com.

+ Read Press Release
- Close Press Release

03.30.20
Excellere Capital Fund III, L.P. Announces Continuation of Commitment Period Following Overwhelmingly Affirmative Vote from Limited Partners

Denver, Co March 30, 2020 – Excellere Partners is pleased to announce the continuation of the commitment period and investment activities of Excellere Capital Fund III, L.P. (the “Fund”) following a vote of all the limited partner interests in the Fund. The Fund entered into an interim period following the death of David Kessenich on January 22, 2020. The interim period would have lapsed and the commitment period continued on May 21, 2020 absent a vote by the limited partners to suspend; however, the limited partners of the fund voted to resume the commitment period early on March 24, 2020.

“We are appreciative and honored by the strong support our limited partners have provided by the early and overwhelmingly affirmative vote to allow the Fund to continue its investment activities,” said Brad Cornell, Ryan Glaws, Matt Hicks and Patrick O’Keefe, Managing Partners of Excellere. “This is a testament to the strength of our entire team and our steadfast focus on deploying a multi-faceted origination strategy, disciplined underwriting program and proprietary value creation process alongside our entrepreneur and management partners.”

The Fund currently has investments in AIS Healthcare, Biocare Medical, Concord Technologies, SePRO, and ParcelShield, which entered into a partnership with Excellere on March 2, 2020.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams to build industry leaders. The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure to enable scalability and rapid growth. Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends. The Firm’s targeted industry sectors include healthcare; industrial technology and services; and business services. For more information about Excellere, please visit https://www.excellerepartners.com/.

+ Read Press Release
- Close Press Release

03.11.20
Excellere Portfolio Company, Biocare Medical, Hires Luis de Luzuriaga as CEO

Pacheco, CA March 11, 2020 – Biocare Medical (“Biocare”), a leading developer of world class immunohistochemistry (“IHC”) and molecular reagents and instrumentation, is pleased to announce that Luis de Luzuriaga has joined the company as Chief Executive Officer.

Mr. de Luzuriaga has spent his entire career in commercial and executive leadership roles within the life sciences tools and diagnostics sector.  Notably, Mr. de Luzuriaga spent six years leading Global Commercial Operations at Leica Biosystems and also served as the Divisional Vice President and General Manager of Abbott Hematology.  Most recently, Mr. de Luzuriaga was the CEO of BIT Group (subsidiary of Messer Group), a leading product development and contract manufacturer for high performance clinical, medical and life science devices.

Mr. de Luzuriaga’s proven ability to drive extraordinary growth and industry leadership within the life sciences tools sector aligns well with Biocare’s strong growth trajectory and reputation for quality diagnostic tools focused on the oncology and immunotherapy markets.  “Since our first interaction with Luis, it was clear that he had the experience, capabilities and expertise to propel Biocare to the forefront of the industry” said Ryan Glaws, Partner at Excellere Partners, “His extensive experience and impressive track record at Leica, Abbott and BIT make him the ideal partner to guide Biocare through this exciting and transformational period in the company’s history.”

“I am excited to join Biocare and work with what I know to be both a dynamic and talented team.  Having previously competed against Biocare, I know first-hand about the quality of the products and reputation in the marketplace.  It is an honor and a privilege to lead this organization, and I am very excited about the future of Biocare” said Mr. de Luzuriaga.

About Biocare Medical
Biocare is a market leader in IHC and molecular diagnostic reagents and instrumentation, including simultaneous Multiplex IHC solutions that provide increased confidence at critical diagnostic decision points, positively influencing patient therapy while accelerating turnaround time.  The company’s customers include clinical and hospital laboratories, pharmaceutical and biotechnology companies, as well as academic, government, and other research institutions.  Biocare offers a comprehensive portfolio of integrated reagents and instrumentation to address the rapidly growing diagnostic and research markets for oncology and immunotherapy.  The company is headquartered in Pacheco, CA, and serves customers around the globe.  Visit www.biocare.net to learn more.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams to build industry leaders.  The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure to enable scalability and rapid growth.  Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  The Firm’s targeted industry sectors include healthcare; industrial technology and services; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com/.

+ Read Press Release
- Close Press Release

03.10.20
Excellere Partners announces a strategic partnership with ParcelShield Holdings

Denver, CO, March 10, 2020 – Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in ParcelShield Holdings, LLC (“ParcelShield”), the leading provider of technology-enabled predictive parcel tracking and engagement services for healthcare clients.  The ParcelShield partnership represents the fifth platform investment in Excellere Capital Fund III, L.P.

Over the past 17 years, ParcelShield (and its predecessor organizations, Dawson Healthcare Solutions and ParcelShield LLC) has established itself as the market leader in pharmacy parcel analytics and rescue services.  ParcelShield’s solutions help pharmacies, hospitals, laboratories, and other healthcare organizations ensure proper handling and timely delivery of critical packages, such as high-dollar cost, time sensitive, temperature-controlled, and life sustaining prescriptions.  Powered by a robust technology platform, these offerings improve coordination from the provider’s office to the patient’s home, enable greater adherence to prescribed drug regimens, and reduce pharmacy costs associated with complex drug therapies by limiting both missed shipments and the need to re-ship expensive and personalized drugs.

“Co-Founders Scott Knight and Doug Dawson are visionaries in the field and have built an exceptional management team, led by Guillermo Sollberger, that produced exceptional historical growth and has positioned the business for sustainable long-term success.  We are honored to partner with the team to continue building on their vision for growth and expand the company’s reach across the healthcare ecosystem while adding complementary capabilities to its solution set,” said Brad Cornell, Partner at Excellere.

Brad went on to say, “Our investment in ParcelShield was prompted by our substantial activity and experience in the pharmacy services space, resulting in recognition of the increasing challenges that pharmacies face in coordinating delivery of critical, high-value prescriptions between healthcare organizations and patients.  With the proliferation of biologics, regenerative medicines, and other high-value therapies, these challenges will only become more acute, and  ParcelShield has developed a novel technology-enabled solution based on sophisticated, proven data models and high-touch coordination services that address these needs in ways that no other provider can.”

Guillermo Sollberger, President and CEO said, “ParcelShield is at an exciting inflection point in its history and we were looking for a partner with a proven track record of helping high-growth companies scale into industry leaders.  We believe there is a substantial opportunity to further enhance ParcelShield’s technology platform and develop novel solutions for existing and new customers.”  Co-Founder Doug Dawson added, “While we had many options, we chose Excellere as they stood out based on their partnership approach, deep knowledge of the healthcare ecosystem and value creation process that will help ParcelShield capitalize on the multitude of exciting expansion opportunities during its next phase of growth.”

ParcelShield’s partnership with Excellere will provide strategic and financial resources to enhance and accelerate the realization of the company’s growth potential. To this end, ParcelShield management and Excellere intend to implement a multi-faceted growth strategy comprised of foundational investments that further enhance ParcelShield’s infrastructure, continued enhancement of the technology platform and artificial intelligence engine, development of complementary capabilities, and expansion into new end markets.

About ParcelShield
ParcelShield offers predictive surveillance technology, driven by machine learning algorithms, to protect critical package deliveries primarily for specialty pharmacies, mail order pharmacies, and specialty pharmaceutical distributors in the United States.  The Company’s primary service offerings include (i) predicting potential route disruptions and package distress using predictive analytics, monitoring shipments in real time through a customer-facing surveillance portal, (ii) intercepting distressed shipments and coordinating successful delivery, and (iii) proactively engaging consumers to coordinate on-time deliveries.  The Company’s predictive services leverage a proprietary data model and analytics platform developed over more than 17 years in the industry to protect high-cost, temperature-sensitive, and urgent, life-sustaining pharmaceuticals.  The Company maintains offices in Orlando, FL, Redmond, OR, and Danville, IL and employs approximately 80 people.  For more information about ParcelShield please visit https://www.parcelshield.com/

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital specializing in partnering with entrepreneurs and management teams. The firm employs a proven research-driven, top-down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  Excellere’s targeted industry sectors include healthcare services and products; industrial technology and specialty chemicals; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com/.

Contact:
ParcelShield Holdings
Guillermo Sollberger


or
Excellere Partners
Brad Cornell

+ Read Press Release
- Close Press Release

02.05.20
Concord Technologies Appoints Bill Shields to Board of Directors

Concord Technologies, a leading provider of cloud-based fax and intelligent document automation software for healthcare providers and enterprises in regulated industries, announces the appointment of Bill Shields to its board of directors to help guide the strategic direction and vision for the company.

Due to lack of interoperability between electronic health record (EHR) systems, healthcare providers continue to exchange the overwhelming majority of patient records in document form, most often via fax machines. The persistence of fax machines is typically viewed as a symbol of an industry resistant to change. In reality, it's an indicator that data interoperability solutions remain out of reach for the majority of healthcare providers, a problem expected to persist for many years to come. Concord is helping providers transition from fax machines to digital, cloud-based faxing augmented with AI-based technology that enables paperless filing of patient documents to EHRs.

"Concord is experiencing a significant and rapid growth as we enable healthcare providers to enhance the interoperability of patient data across the continuum of care and reduce the burden of regulatory paperwork consuming clinicians' time," said Chris Moore, Founder and President of Concord Technologies. "Bill's wealth of leadership experience in the healthcare industry will help us sustain the growth of our organization as we are looking to connect even more closely with the markets we serve."

Shields brings to Concord 30 years of strategic management experience in healthcare and pharmacy companies. He is currently on the board of Dallas-based Advanced Infusion Solutions, where he previously served as CEO. Shield's other roles include President of MTS Medication Technologies, CEO of Artromick International, SVP at AmerisourceBergen, and President of PharMerica.

"As complexity and interoperability challenge the healthcare ecosystem, Concord is successfully leveraging proven technology to automate and streamline document workflows," said Bill Shields. "Chris Moore has put together a great team dedicated to making the delivery of care more effective and accurate. I am excited to join the board of directors."

Concord will be attending HIMSS20 in Orlando, March 9 – 13, and is available for meetings at booth #634. For further information about Concord, visit concord.net.

About Concord Technologies
Concord Technologies helps organizations in healthcare and other highly regulated industries automate their manual and document-intensive processes. Concord's cloud fax service is the dominant, cloud fax solution in healthcare in the U.S. and is responsible for the delivery of more than a billion healthcare documents each year. Concord is headquartered in Seattle, Washington and employs more than a 100 people in the USA and India. www.concord.net.

+ Read Press Release
- Close Press Release

01.23.20
David L. Kessenich: In Memoriam

It is with great sadness that we announce the passing of our dear friend David Kessenich, a Managing Partner and Co-Founder of Excellere Partners. David passed as a result of complications from his multi-year battle with cancer.

Having grown up on a third generation farm in western Iowa, David was the first person in his family to obtain a college education, graduating with honors from Creighton University and receiving an MBA from the University of Chicago. His professional career began as an advisor to middle market companies raising debt and equity for growth initiatives, and later as a private equity professional. David ultimately conceived of and co-founded Excellere based on his belief in a better approach to supporting entrepreneurs and management teams through private equity-sponsored partnerships. Over the ensuing 13 years, the firm has generated extraordinary investment returns with its entrepreneurs and LP investment partners, ranking as one of the top performing private equity investment firms globally.

David’s creativity, determination, passion and commitment to partnership will forever remain a foundation of our firm, and his legacy will be remembered through our firm’s value statement - Do the Right Thing, the Right Way, with Excellence. More importantly, however, David was a loving and committed husband, father and family man, as well as a caring friend and role model. His mentorship has had a tremendous impact on our firm’s next generation of investment leadership team of, Matt Hicks, Patrick O’Keefe and Ryan Glaws, who have been with the firm since inception, and Brad Cornell for more than nine years.

We will honor his memory by dedicating ourselves to continuing the work he loved so much. On behalf of the entire team at Excellere Partners, we extend our deepest sympathies to his wife, Colleen, their children Jack, Caroline and Andrew, and his entire family. David was an inspiration to all who knew him and he will be dearly missed.

+ Read Press Release
- Close Press Release

10.14.19
Excellere Portfolio Company, Biocare Medical, Appoints Nicolas Barthelemy as Executive Chairman

Pacheco, CA October 14, 2019 – Biocare Medical (“Biocare”), a leading developer of world-class immunohistochemistry (“IHC”) and molecular reagents and instrumentation, announced today the appointment of Nicolas Barthelemy as Executive Chairman.  Mr. Barthelemy brings over 25 years of executive leadership experience in the life sciences and diagnostic tools industry.  He most recently served as CEO & President of Biotheranostics, a molecular diagnostics company.  Additionally, Mr. Barthelemy held multiple executive leadership positions at Life Technologies, a leading developer of Life Science solutions, including roles as Chief Commercial Officer and President of the Cell Systems Division.  Prior to leading commercial operations for Life Technologies, Mr. Barthelemy served in senior leadership roles at Biogen and Merck.

As Executive Chairman, Mr. Barthelemy will provide Biocare with strategic leadership as it continues to execute its vision as the preeminent provider of IHC reagents and instrumentation focused on clinical diagnostics and research in the oncology and immunotherapy sectors.  “Nicolas has been a key member of Biocare’s board since joining the team in April 2018, and we are excited about the impact he will have in his expanded role with the organization,” said Ryan Glaws, Partner at Excellere Partners.  “His extensive industry experience within the life science tools space and proven track record of driving growth across multiple organizations make him an ideal leader to support Biocare during this period of rapid expansion.”

“Biocare has reached an exciting inflection point in the company’s history, driven by its commitment to providing the highest quality IHC reagents and associated instrumentation solutions for the clinical diagnostic, research and pharma markets.  I look forward to supporting the management team in executing on our mission to drive positive outcomes for the patients and families that have seen their lives forever altered by a cancer diagnosis,” said Mr. Barthelemy.

About Biocare Medical
Biocare is a market leader in IHC and molecular diagnostic reagents and instrumentation, including simultaneous Multiplex IHC solutions that provide increased confidence at critical diagnostic decision points, positively influencing patient therapy while accelerating turnaround time.  The company’s customers include clinical and hospital laboratories, pharmaceutical and biotechnology companies, as well as academic, government, and other research institutions.  Biocare offers a comprehensive portfolio of integrated reagents and instrumentation to address the rapidly growing diagnostic and research markets for oncology and immunotherapy.  The company is headquartered in Pacheco, CA, and serves customers around the globe.  Visit www.biocare.net to learn more.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams to build industry leaders.  The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure to enable scalability and rapid growth.  Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  For more information about Excellere, please visit https://www.excellerepartners.com.

+ Read Press Release
- Close Press Release

09.26.19
10 Tips for Preparing for and Managing a Private Equity Investor Relationship

Private equity investment is an option that should be considered by any company looking to achieve growth capital or liquidity. Whether you are a founder-owned business looking for a first-time private equity investment or a company that has an existing private equity investor who is looking to exit in a recapitalization transaction, understanding the current private equity landscape is key to preparing for a transaction and managing the relationship on a go-forward basis. In this article, we outline five tips for companies preparing for a private equity investment and five tips for managing a new private equity relationship post-transaction.

Read More »

+ Read Press Release
- Close Press Release

03.12.19
Quality of Earnings: The Most Important Term You Probably Don’t Know

For those of you that have been through a recent business sale process, quality of earnings (Q of E) is a phrase that may still produce night sweats. For the rest of you, be aware that it is fast becoming one of the most important concepts in managing and evaluating your business.

Read More on Pharma's Almanac »

+ Read Press Release
- Close Press Release

02.27.19
Excellere Partners Announces Promotions and Team Addition

Denver, CO – February 27, 2019.  Excellere Partners, a leading Denver-based private equity firm specializing in partnering with entrepreneurs and management teams through recapitalizations and management buyouts, is pleased to announce the promotion of Mike Vieth to Principal, the promotions of Nick Coleman and Matt Halverson to Vice President, and the addition of Tyler Ashley as Origination Associate.

“We are very proud of the team that we are building at Excellere, and we are excited to be developing strong talent such as Mike, Nick and Matt within our organization,” said Brad Cornell, Partner at Excellere Partners.  “Since joining Excellere, Mike, Nick and Matt have each demonstrated outstanding dedication, broad investment experience with superior results, and excellent leadership and values that are integral to our firm.  We are pleased to announce their promotions and look forward to their continued success and contributions to the firm in their new positions.  Furthermore, the addition of Tyler provides even more depth to our firm-wide origination platform, and we are excited to have him join us in support of our sourcing efforts. ”

Mike Vieth joined Excellere Partners in 2014 as an Associate, and has been a key team member on portfolio companies TrialCard Incorporated, Two Labs Pharma Services and Concord Technologies.  Nick Coleman joined Excellere Partners in 2013, and has been a key team member on portfolio companies LucidHealth, Medlogix, and Biocare Medical.  Matt Halverson joined Excellere Partners in early 2014, and has been a key team member on portfolio companies AIS Healthcare, Mentis Neuro Health and SePRO.  Mike, Nick and Matt are all responsible for evaluating and executing new investment opportunities, supporting management teams in the implementation of portfolio company value creation initiatives, and pursuing liquidity opportunities through dividend recapitalizations and exit transactions.

Tyler Ashley joins Excellere from an East Coast-based middle market buyout firm where he focused on sourcing new transactions and building relationships with business owners as well as intermediaries.  Mr. Ashley earned an MBA from Babson College F.W. Olin Graduate School of Business and a Bachelor of Science in Business from Wake Forest University.

About Excellere Partners

Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across three funds, and specializes in partnering with entrepreneurs and management teams through recapitalizations and management buyouts.  The Firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on emerging companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  The Firm’s targeted industry sectors include energy, power, and infrastructure products and services; healthcare; industrial technology and services; and business services.  For more information about Excellere, please visit  https://www.excellerepartners.com

+ Read Press Release
- Close Press Release

02.12.19
SePRO Corporation announces a strategic partnership with Excellere Partners

Carmel, IN, Tuesday, February 12, 2019 – Bill Culpepper, President & CEO of SePRO Corporation announced today that Excellere Partners, a private equity firm focused on partnering with entrepreneurs and management teams, has made a strategic investment in SePRO Corporation.

Patrick O’Keefe, Partner at Excellere Partners stated, “Excellere was in search of partnership opportunities in the agricultural and water segments of the specialty chemicals industry that offer a solution comprised of high performance products and proprietary technical services – SePRO fits these criteria perfectly. Founder Bill Culpepper is a recognized leader in the industry and has built a strong management team with a shared commitment to offering customers the most effective solutions in the market. As a result, SePRO is poised to continue its strong organic growth while also leveraging Excellere’s resources to pursue partnership opportunities and acquisitions in the industry.”

Over the past 25 years, SePRO has established itself as an innovator of specialty products and services that satisfy the unique needs of its customers. The company offers products that manage invasive weeds and algae in aquatic environments, plant growth regulators, herbicides, insecticides, and fungicides for the turf and greenhouse markets, as well as herbicides for the specialty agriculture markets. SePRO has a robust pipeline of new products in development including multiple novel biologic solutions.

Bill Culpepper said, “An exciting opportunity exists for SePRO to create additional value to customers across the markets we serve by expanding the breadth and depth of our products and services. It is clear to us that Excellere supports SePRO’s commitment to solving its customer’s most complex challenges. SePRO anticipates the Excellere partnership will enable the successful next phase of the company’s growth.”

Since its beginning, SePRO has invested to create research, manufacturing and marketing capabilities to serve its customers. The partnership with Excellere will provide resources to enhance and accelerate the company’s growth opportunities. SePRO and Excellere intend to implement a multi-faceted growth strategy comprised of investments that further enhance SePRO’s infrastructure; continued penetration of its existing products; commercialization of a pipeline of new technologies; and complementary partnerships with other leading agricultural and water-focused specialty chemical businesses.

About SePRO Corporation
SePRO Corporation is dedicated to discovering and developing sustainable solutions. Founded in 1994, SePRO’s mission is to provide plant protection and plant management products and services that fit specialized market needs. The company acquires, develops, manufactures, and markets value-added products and services that satisfy the unique needs of their customers. In addition, SePRO has partnered with several of the top agriculture chemical companies to develop chemistries for use in SePRO’s key markets. Central to that product innovation is the 410-acre SePRO Research & Technology Campus (SRTC) in Whitakers, NC. For more information about SePRO please visit https://www.sepro.com

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams. The firm employs a proven research-driven, top-down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth. Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends. Excellere’s targeted industry sectors include industrial technology and specialty chemicals; healthcare services and products; energy, power, and infrastructure services and products; and business services. For more information about Excellere, please visit https://www.excellerepartners.com

+ Read Press Release
- Close Press Release

01.30.19
Excellere Partners Announces Investment in Concord Technologies, a Leading Provider of Healthcare Interoperability and Automation Solutions

Denver, CO, January 30, 2019 - Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in Concord Technologies (“Concord”), a leading provider of secure, cloud-based interoperability and automation technology for healthcare and other document-intensive industries.  Based in Seattle, Washington, Concord’s solutions promote interoperability through the efficient and secure exchange of large quantities of critical data.  Concord’s AI technology underpins the company’s content extraction, recognition, search, and automation platform, enabling customers to efficiently manage critical document processes.  Additionally, the company’s most recent workflow platform, NEXTSTEP, unlocks the power of unstructured data, enabling customers to create and integrate vital datasets from a variety of unstructured data sources.

“We are extremely excited to partner with Chris Moore and the entire Concord team, as we look to support their vision for becoming the leader in healthcare process automation and integration,” said Ryan Glaws, Partner with Excellere. “Concord’s unique service offering addresses critical needs within the broader healthcare ecosystem, including information security and system interoperability. With its AI-powered workflow, Concord’s solutions provide significant and tangible value to customers, enabling them to send, receive, ingest, and direct large amounts of inbound and outbound unstructured data, which enables greater efficiency and ultimately enhances the timely and accurate delivery of patient care.”

“Concord has been built on a commitment to provide solutions that help our customers use their data securely and efficiently,” said Chris Moore, founder and CEO of Concord.  “We continue to experience tremendous growth and have sought a partner with a proven track record of helping high-growth companies scale into industry leaders.  We are thrilled to partner with the Excellere team and believe their unique combination of healthcare expertise and their value creation process will help to position Concord properly for the massive growth that lies ahead.”

Cascadia Capital served as the exclusive financial advisor to Concord.

About Concord Technologies
Concord Technologies is a Seattle, Washington-based provider of interoperability and automation solutions focused on healthcare and other document-intensive industries.  Serving over 1,500 customers, Concord’s solutions help transfer, process, and integrate unstructured data within customers’ existing the systems and operational processes.  For more information, please visit: http://www.concord.net

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams.  The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on differentiated and growth-oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  Excellere’s targeted industry sectors include: healthcare; energy, power and infrastructure services and products; industrial technology, specialty chemicals; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com

+ Read Press Release
- Close Press Release

01.16.19
Supporting faculty leadership in entrepreneurship and private equity

'Do the right thing the right way, with excellence.' Those are the words David Kessenich, '96, lives by. That consistent focus on excellence is how his firm, Excellere Partners (E.P.), became one of the leaders in the private equity field.

Read More on The University of Chicago Booth School of Business »
Read More on Polsky Center for Entrepreneurship and Innovation »

+ Read Press Release
- Close Press Release

10.25.18
Two Labs Acquires Pennside Partners Ltd.

Company continues to expand suite of solutions with addition of market insights, benchmarking and competitive intelligence services

DENVER, Colorado (October 25, 2018) - Industry-leading pharmaceutical services company, Two Labs, an Excellere Partners platform company, today announced it has acquired Pennside Partners Ltd., an international provider of market insights, benchmarking and competitive intelligence services for the pharmaceutical, biotech, and medical device sectors. Terms of the agreement were not disclosed.

The partnership is a testament to the companies’ shared commitment to bettering patients’ quality of life through improving pharmaceutical product access. The companies’ combined subject-matter expertise, broad experience across therapeutic areas, and global reach creates a powerful combination that will allow Two Labs to provide enhanced services throughout the product lifecycle from pre-launch through loss of exclusivity.

In December 2016, Two Labs received a strategic investment from Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies. Since forming the partnership, Two Labs and Excellere have pursued a targeted buy-and-build strategy focused on enhancing the company’s service portfolio through developing and acquiring complementary, value-added solutions, extending its geographic footprint, and expanding its customer base. The acquisition of Pennside Partners marks the Company’s second strategic acquisition in 2018, following its acquisition of MKO Global Partners, a provider of pricing and managed markets services in February.

“In the highly competitive pharma market, it is crucial to stay at the forefront of the industry by providing unparalleled clinical product insights and strategic commercialization roadmaps,” said Rich Wartel, CEO of Two Labs. “This acquisition allows us to offer an even more comprehensive portfolio of integrated services to meet our clients’ evolving commercialization needs, giving them the ability to deliver transformative, life-saving products to patients across the globe.”

Brad Cornell, Partner at Excellere added, “The Two Labs leadership team has been laser-focused on adding complementary services that respond to the evolving needs of their biopharmaceutical clients, and the Pennside capabilities are a perfect fit with that strategy. Combined with the MKO Partners acquisition earlier in the year, Two Labs now has established a true global offering that can support its clients’ access challenges across the full product life cycle.”

About Two Labs
Two Labs is a leading pharmaceutical services company that provides a portfolio of product commercialization and lifecycle services to pharmaceutical manufacturers. Since its inception in 2003, Two Labs has worked with over 380 manufacturers. This includes supporting over 150 emerging manufacturers with their first product and over 230 pharmaceutical manufacturers with in-market products from pre-launch to loss of exclusivity. For more information, visit www.TwoLabs.com.

About Pennside Partners Ltd.
Pennside Partners Ltd is a leading international business development consulting firm providing market insights, benchmarking, and competitive intelligence for the pharmaceutical, biotech, and medical device sectors. Pennside has been a trusted partner with many of the largest pharmaceutical and biotech companies for over 25 years, with a growing presence among small and mid-sized players. For more information, visit www.Pennside.com.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of capital across three funds, and specializes in partnering with entrepreneurs and management teams. The Firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth. The Firm’s targeted industry sectors include: healthcare services and products; energy, power and infrastructure products and services; industrial technology, specialty chemicals and services; and business services. For more information, visit www.excellerepartners.com

+ Read Press Release
- Close Press Release

08.14.18
Excellere Partners Announces Two Add-on Acquisitions for it’s Medlogix Portfolio Company

Denver, CO, August 14, 2018 - Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams in emerging growth companies, announced today that its portfolio company, Medlogix, LLC (“Medlogix”) has acquired Minneapolis, Minnesota-based Integrity Medicolegal Enterprises (“Integrity”), and Southfield, Michigan-based Michigan Evaluation Group (“MEG”) – two premier providers of independent medical examinations (IMEs), medical record reviews, peer reviews, and related services.

Medlogix seeks to deliver a comprehensive suite of innovative medical claims management services to insurance carriers, claims administrators, and employers in the auto, workers’ compensation, and group health markets by leveraging its robust technology-enabled platform and deep clinical expertise. The acquisition of Integrity and MEG represents a strategic combination of clinically focused organizations that are dedicated to delivering effective and quantifiable claims management solutions to their carrier and administrator clients.

“Integrity, MEG and Medlogix all share a culture of commitment to deliver exceptional medical outcomes that drive increased client satisfaction,” said Craig Goldstein, President of Medlogix.  “Our partnership with these two organizations will greatly expand our physician network, add unique domain expertise, and further augment our ability to deliver a comprehensive suite of solutions to a growing base of clients in the Midwest corridor. Our collective customers are going to be very pleased with the expansion of our resources and enhanced ability to service their needs.”

Matt Hicks, Partner with Excellere, added, “Medlogix has been a leader within its core markets for more than 20 years, so we’re excited to be supporting the management team in executing their vision for delivering innovative medical claims management solution on a national scale.  With Integrity and MEG, we found two like-minded organizations with parallel cultural values and excellent, long-standing reputations for quality, service, and client satisfaction.”

About Medlogix
Medlogix is a technology-driven, clinically-based medical claims management provider specializing in managed care solutions that deliver exceptional outcomes. Medlogix offers an end to end, integrated medical management solution powered by MyMedlogix® proprietary technology.  Through an exception-based workflow, recommendations from highly qualified medical professionals, and access to a directly contracted network of premier health care providers, Medlogix delivers an efficient, disciplined, and scalable medical claims process suite of solutions. Medlogix develops technology which achieves savings you can measure and see by eliminating redundancies and reducing manual processes.  Learn more about the Medlogix story at www.medlogix.com.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams.  The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on differentiated and growth oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  Excellere’s targeted industry sectors include: healthcare services and products; energy, power and infrastructure services and products; industrial technology, specialty chemicals; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com.

+ Read Press Release
- Close Press Release

04.05.18
Premier Imaging Ventures Announces Name Change to LucidHealth

New brand reflects the organization's evolution and vision for the future

COLUMBUS, Ohio, April 5, 2018 /PRNewswire/ -- Premier Imaging Ventures, a physician-owned and -led radiology management company, today announced its name change to LucidHealth.

"Our business has evolved significantly over the last several years, and our new name is more reflective of who we have become and where we are going as an organization," said Marcia Flaherty, CEO of LucidHealth. "Today, we have the proven technology and talent to bring about real change in the radiology community, and our new brand reinforces the clarity we deliver to our physician partners about their future."

The brand's name change reflects LucidHealth's vision for the future of radiology — one that will enable private radiology groups to do more and perform better. LucidHealth's belief is simple: All patients should have access to the highest quality subspecialized imaging care, regardless of facility size or location. In keeping consistent with its vision and belief, LucidHealth's mission is to empower physician-led radiology groups with the technology and resources necessary to deliver world-class, subspecialized care to all patients within the communities they serve.

Central to LucidHealth's offering is superior technology. RadAssist is a proprietary application that allows disparate systems to be combined into a single workflow. This innovative software also manages diagnostic images across multiple platforms and enhances work processes for physicians. This increases efficiency, improves quality of care, lowers costs for patients and delivers better outcomes. RadAssist, built by radiologists, for radiologists, offers real-time clinical and operational analytics and has been in clinical use for over 10 years.

"Our technology allows radiologists to offer industry-leading turnaround times, exceptional subspecialized care and analytics that prove clinical value," said Mark Alfonso, M.D., chief medical officer of LucidHealth. "LucidHealth consolidates our unique assets, allowing us to offer other groups cost-effective, revolutionary technology that elevates access to care."

About LucidHealth
LucidHealth is a physician-owned and -led radiology management company. We partner with radiology groups to provide the technology and resources to increase the strategic value of their practices nationwide. Our belief is that all patients should have access to the highest quality of subspecialized imaging care, regardless of facility size or location. Our mission is to empower independent radiology groups to deliver world-class, subspecialized care to all patients within the communities they serve. For more information, please visit http://www.lucidhealth.com.

About Riverside Radiology and Interventional Associates
Riverside Radiology and Interventional Associates, a LucidHealth company, is a leading provider of professional radiology services to hospitals and other healthcare providers. Formed in 1980, Riverside Radiology and Interventional Associates is one of the largest private radiology practices in the United States. By using its proprietary software, Riverside Radiology has developed industry-leading workflow and clinical processes and a broad spectrum of physician support services. For more information, please visit http://www.riversiderad.com.

Media Contact:
Kelley Holsten
Sales & Marketing Operations Manager

SOURCE LucidHealth

+ Read Press Release
- Close Press Release

02.06.18
Consolidated Services Group Looks to the Future with a Powerful New Branding Campaign and Visual Identity

Hamilton, NJ (February 6, 2018) Medical claims management innovator Consolidated Services Group (CSG) today introduced a new national brand identity designed to unify its brand and convey its industry-leading proficiency managing complex claims and exceptions.

Beginning on February 6, 2018, CSG will change its name to Medlogix®, which aligns the company’s corporate brand with its groundbreaking Medlogix® technology. The company also unveiled a new logo and introduced the tagline, “Expect exceptional,” as part of the brand refresh.

“We are proud of our CSG name and the distinguished brand it represented for over three decades. However, we made the strategic decision to evolve our brand identity to reflect the transformative growth and development our company is undertaking,” said President Craig Goldstein. “Medlogix® is a strong name that evokes smart medical decisions grounded in logic.  It enjoys significant brand recognition in our key markets and we believe that, paired with our new tagline and graphic style, it conveys the complexity of what we do in a positive, compelling way.”

Since announcing a major investment by the private equity firm Excellere Partners in June 2017, CSG has hired key senior managers, steadily expanded its team, and advanced its sales and service capabilities to support its continued growth.

“We consider this another in a series of great milestones for our company. Together with our strong industry reputation for achieving great outcomes in complex markets and rock solid client relationships, we believe a unified brand can help us leverage company awareness to attract top talent in markets across the United States,” Goldstein said. “The Medlogix® brand will propel us into the future with claims management professionals and solutions that consistently rise to the challenge of taking on the toughest cases and most difficult markets on behalf of our clients.”

As a medical claims management innovator, Medlogix® delivers a proven mix of technology and medical expertise that enables its clients to confidently navigate some of the most highly regulated markets with the largest exposures producing maximum returns. The company’s offerings include seamless collaboration through its proprietary Medlogix® technology; recommendations from highly qualified medical professionals; and access to a national network of premier health care providers. CSG’s national PPO network offerings will be marketed under MedlogixPPO™, with its flagship CHN PPO retaining its current brand.

About Medlogix®
Medlogix® (formerly Consolidated Services Group) is a technology-driven, clinically based medical claims management provider. We offer a comprehensive solution for streamlining insurance claims, backed by more than 35 years of claims management experience and powered by advanced technology. Our complete, integrated solution, includes seamless collaboration through our proprietary technology; recommendations from highly qualified medical professionals; and access to a nationwide network of premier health care providers. What makes us truly different, however, is the standard we set for ourselves in terms of service to our customers. It begins by coming to work each day with the goal of improving upon everything we do. Whether it's our process, our technology, an idea that advances the Industry, or any aspect of the customer experience, we are committed to making a positive impact. And it is why we can say with confidence, "Expect exceptional." Visit www.medlogix.com to learn more.

+ Read Press Release
- Close Press Release

12.04.17
Robert A. Martin: In Memoriam

Denver, CO – Excellere Partners is deeply saddened to announce the passing of Rob Martin, a Managing Partner and Co-Founder of the firm and a dear friend. Rob passed as a result of complications from his battle with cancer after recently celebrating his 69th birthday.

Rob had a long and distinguished career as an entrepreneur (founding two businesses), as an investment banker advising business owners, and most recently as a private equity investor partnering with entrepreneurs. Throughout his career, Rob was a tireless champion for business owners.

In 2006, Rob co-founded Excellere Partners with David Kessenich to pursue a vision for supporting the aspirations of entrepreneurs and providing the necessary resources for their emerging growth companies to become industry leaders. Over the ensuing 11 years, the firm has generated extraordinary investment returns with its entrepreneurs and LP investment partners, ranking as one of the top performing private equity investment firms globally.

“Rob’s sense of humor, creativity, determination, passion and continuous challenge of the status quo will forever remain a foundation of our firm,” said David Kessenich, Managing Partner and Co-Founder of Excellere Partners. “His legacy will be remembered through our firm’s value statement - Striving to Do the Right Things, the Right Way, with Excellence, which was one of the first things that we developed when starting the firm.” Kessenich continued, “Rob was a world-class networker and an inspiring leader. His guidance and mentorship have had a tremendous impact on our firm’s next generation of investment leadership team of Matt Hicks, Patrick O’Keefe and Ryan Glaws, who have been with the firm since inception, and Brad Cornell for almost seven years.

“No words can adequately express our sadness at Rob’s death or our gratitude for the opportunity to have worked with him. We will honor his memory by dedicating ourselves to continuing the work he loved so much. On behalf of the entire team at Excellere Partners, we extend our deepest sympathies to his wife Karen and his entire family.” Kessenich concluded, “Rob was a huge presence in our lives and he will be dearly missed.”

In lieu of cards or condolences, Rob’s wishes were for donations to the Denver Rescue Mission, which provide services to people experiencing homelessness, at www.denverrescuemission.org or P.O. Box 5206, Denver, CO 80217.

+ Read Press Release
- Close Press Release

11.05.17
Urgent care clinics have taken off in the past decade — and it shows that health care businesses acting like Amazon will gain an edge
  • Going to the doctor isn't a very good experience.
  • To survive, health care businesses need to start thinking about the customer.
  • It's more important than any policy decision Washington makes.
  • Urgent care centers are an example of applying the Amazon model to health care.

Why is it that when I walk into a restaurant or store where I'm spending $15, I'm often treated better than when I go to a doctor's office where I'll easily spend $150?

We've all been there. Sick and suffering, you wait hours for the doctor's office to have an opening, and you limp into their lobby. A grump at the front desk pushes a clipboard at you, and you spend 15 minutes filling out a paper form with the same information you've provided twelve times before. There is a long wait, and you need to postpone an important call with your office.

It is that experience, to which we've become all-too accustomed, that will be the life or death of many healthcare businesses in the next ten years - much more so than any policy decision made out of Washington.

As more cost is borne by consumers, and healthcare demand and expense rapidly expands, healthcare models will need to change.

Just look at the way urgent care centers have taken off in the past decade.

Urgent care doesn't offer care that's unique to what any doctor or emergency room provided in the past. They've had success on the basis of easy parking and extended hours. Any healthcare business that is acting like Amazon, by taking the service to the customer, will gain an edge.

This 'consumerization of healthcare' is just one of the private sector dynamics to watch.

We have an aging population, a diabetes wave building on the horizon and genomics breakthroughs that can utterly shuffle the deck for how healthcare is delivered.

Insurance policy will have some sway on profits. But ultimately, any business that is wholly dependent on being paid by insurers based on numbers of patients and billable services is already on the wrong side of the trend.

What type of companies will succeed?

Beyond catering to the consumer, there are other earmarks of successful healthcare companies in this new healthcare order.

For instance, investors should be on the lookout for anyone who has a shot at curing a disease. In our current healthcare system, we're great at managing symptoms and conditions. We need a moonshot breakthrough, just to show that it can be done. Companies and researchers with any chance at developing cures for cancer, Alzheimer's or ALS are worth funding.

Next, we aren't addressing the healthcare system's major cost drivers — chronic illnesses and injuries, the brain injuries, strokes, cardiac issues, diabetes, the knee and hip replacements. Instead, we focus on acute injuries and sicknesses -- colds, flu, broken legs. This emphasis is unwise.

Any company that can create systemic change to prevent and manage chronic illness through technology or new therapeutic models will win. Companies that use technology to allow chronically ill patients to better manage their condition or enable them have a more fulfilling life will be successful.

Take a stroke survivor, for example. Instead of that person being in an institution, imagine a care model where he or she could be at home and cared for less expensively. We need to reduce hospitalizations, emergency room visits, and custodial care.

Third, care coordination remains highly fragmented among multiple stakeholders whose interests aren't always aligned. People want more and better care. Insurers want to grow revenue and pay out less . Providers and the government need to reduce costs. How can such competing interests deliver value? Honestly, I'm not sure it can be done. But we've got to do better.

Finally, Americans increasingly believe, as most of the rest of the world already does, that healthcare should not be denied for financial reasons. That raises questions about who pays for what costs and what kind of care and services are considered universally accessible and affordable. Solving for that is a major actuarial and societal challenge, and anyone who can determine how to cover these bases will have a good story to tell.

I'd be willing to bet that some smart entrepreneurs have answers to many of these big problems. And that means the healthcare industry is about to get much healthier in the next ten years. Let's hope we all do, too.

Mike Geldart is a partner at Excellere Partners, a private equity firm in Denver, CO, specializing in healthcare with investment experience in urgent care, pain management, anesthesiology, radiology, specialty pharmacy, pharma services and manufacturing, and life sciences.

+ Read Press Release
- Close Press Release

08.25.17
Excellere Partners Announces Investment in Biocare Medical, a Leading Provider of Immunohistochemistry Instrumentation and Reagents
Investment Represents 1st Platform in Excellere Capital Fund III, L.P.

Denver, CO, August 25, 2017 - Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in Biocare Medical (“Biocare”), a leading provider of immunohistochemistry (IHC) instrumentation, as well as a full range of reagents for IHC and molecular testing.  The Biocare partnership represents the first platform investment in Excellere Capital Fund III, L.P.

An innovator in the sector, Biocare is a market leader in simultaneous Multiplex IHC tests, which provide increased confidence at critical diagnostic decision points, improving patient therapy while accelerating turnaround time.  “We’re thrilled to have the opportunity to partner with Roy Paxton Yih and the entire Biocare team, and are excited to support their vison for building a best-in-class industry leader focused on IHC and molecular diagnostic products,” said Ryan Glaws, Partner at Excellere. “We identified the reagents and diagnostics products sector several years ago as an attractive area in which to execute Excellere’s value creation strategy.  We have dedicated significant resources to pursuing a reagent platform that has a differentiated product offering, global customer base, commitment to R&D, and a passionate leadership team.  In Biocare, we have found both an exceptional business as well as a proven management team,” continued Mr. Glaws.

Biocare’s partnership with Excellere will provide the strategic and financial resources to enhance and accelerate the company’s growth opportunities.  To this end, Biocare management and Excellere intend to implement a multi-faceted growth strategy comprised of foundational investments that further enhance Biocare’s scalable infrastructure; identified organic growth initiatives in existing and new markets; and complementary strategic partnerships with other leading reagent and diagnostic businesses.

“We have an outstanding opportunity to partner with Excellere, which has a proven track record of supporting founder-led businesses in achieving transformative growth.  Over the last 20 years we have not only built a strong and growing company, but more importantly, have developed innovative products that enhance the disease diagnosis and monitoring process and ultimately save lives.  While we had many options, we chose Excellere as our partner based on their track record and passion for supporting emerging growth companies.  We believe that our product suite and service model uniquely position Biocare to meet the evolving demands of clinicians and researchers across the globe,” said Roy Paxton Yih, Biocare co-founder and Chief Executive Officer.

“This partnership is perfectly aligned with our firm’s founding philosophy to invest in entrepreneurial healthcare businesses that are patient-centric, while also creating value for the clinicians, institutions, and other stakeholders in the healthcare ecosystem.  Together, Biocare management and Excellere will further strengthen the company’s presence, not only in the U.S., but in other attractive markets by partnering with leading reagent and diagnostic tools businesses as well as expanding the company’s product offering.” Mr. Glaws explained.

About Biocare
Biocare is a market leader in IHC and molecular diagnostic reagents, including simultaneous Multiplex IHC tests that provide increased confidence at critical diagnostic decision points, positively influencing patient therapy while accelerating turnaround time.  The company’s customers include clinical and hospital laboratories, pharmaceutical companies, and biotechnology companies as well as academic, government, military, and other non-profit laboratories.  Biocare offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets with novel tissue immunohistochemistry and in situ hybridization methods.  The company is headquartered in Pacheco, CA, and has a global distribution network.  Visit www.biocare.net to learn more.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams.  The firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on differentiated and growth oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  Excellere’s targeted industry sectors include: healthcare services and products; energy, power and infrastructure services and products; industrial technology, specialty chemicals; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com

+ Read Press Release
- Close Press Release

06.21.17
Excellere Partners Announces Strategic Investment in Leading Medical Claims Management Provider Consolidated Services Group (CSG)
Investment Represents 11th Platform in Excellere Capital Fund II, L.P.

Denver, CO, June 21, 2017 - Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in Consolidated Services Group (CSG), a leading technology-enabled and clinically-based medical claims management provider serving auto insurance carriers, workers’ compensation administrators and group health insurers, specializing in managed care, utilization review and bill review services.  The CSG investment represents the eleventh platform investment in Excellere Capital Fund II, L.P.

An innovator in the sector, CSG delivers a comprehensive suite of proven medical claims management solutions, clinical expertise, and proprietary preferred provider organization that enable its clients to confidently navigate the entirety of the medical claims management process—from initial filing through close. CSG’s offerings include seamless collaboration through its proprietary technology platform, medlogix®; recommendations from highly qualified medical professionals; and access to a national network of premier health care providers.

“Controlling medical claims costs while improving outcomes represents a significant challenge to insurance carriers, administrators and health plans across the country,” said Matt Hicks, Partner at Excellere Partners. “Excellere looks to partner with organizations that offer innovative ways to address these challenges and CSG is a strong fit for that criteria. Given CSG’s exceptional customer value position, its highly experienced management team, and the valuable benefits its technology and services deliver to insurance providers, injured parties and all stakeholders in the claims process, we are thrilled to support this team and help achieve its vision for growth.”

“At CSG, the desire to improve outcomes drives everything we do. Excellere’s philosophy and experience around supporting clinical outcomes-centric businesses clearly sets them apart,” said Craig Goldstein, CEO at CSG. “The entire Excellere team intuitively understood the CSG value proposition and we look forward to advancing the industry with fresh ideas and delivering unmatched value to our clients nationwide as they make informed choices for their medical claims management needs.  As we embrace this new partnership, we will look to deploy new growth capital to further our technology platform, engage new markets and acquire new, complementary capabilities, while maintaining the highest standards of innovation, performance, service and integrity.”

About Consolidated Services Group
Consolidated Services Group (CSG) is a technology-driven, clinically-based medical claims management provider specializing in managed care, utilization review and bill review services. CSG offers a complete, integrated solution, including seamless collaboration through our proprietary medlogix® technology; recommendations from highly qualified medical professionals; and access to a nationwide network of premier health care providers. CSG’s powerful mix of medical expertise, proven processes and innovative technology delivers a more efficient, disciplined insurance claims process. The result is lower expenses and increased productivity for the auto insurance and workers’ compensation insurance carriers, third party administrators (TPAs) and government entities we serve. Visit www.csg-inc.net to learn more.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of committed capital across Fund I, Fund II and Fund III, specializing in partnering with entrepreneurs and management teams.  The Firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on differentiated and growth oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  The Firm’s targeted industry sectors include: healthcare services and products; energy, power and infrastructure products and services; industrial technology, specialty chemicals and services; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com

+ Read Press Release
- Close Press Release

01.10.17
Excellere Partners Announces Its Investment in Two Labs Marketing
Investment Represents 10th Platform in Excellere Capital Fund II, L.P.

Denver, CO, January 10, 2017 - Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in Two Labs Marketing, a leading provider of product commercialization solutions to pharmaceutical manufacturers, offering strategic consulting and implementation services throughout the full product lifecycle. The Two Labs Marketing investment represents the tenth platform investment in Excellere Capital Fund II, L.P.

Founded in 2003 and headquartered in Powell, Oho, Two Labs Marketing provides innovative solutions for pharmaceutical manufacturers’ most prevalent commercialization challenges. The company leverages more than 13 years of experience and over 115 discrete product launches to implement proven strategies that are customized to each client’s therapeutic class, distribution channel and patient needs. Through its comprehensive commercialization services offering, the company manages clients’ product launch, compendia and lifecycle management, trade management, product state licensing compliance and e-prescribing management services.

David Kessenich, Co-Founder and Managing Partner at Excellere Partners, commented, “Our thesis in outsourced pharmaceutical services is based on a number of favorable industry trends, including the increased utilization of pharmaceuticals in patient treatment regimens, the sustained growth in specialty pharmaceuticals and the complexity associated with the distribution and administration of these therapies, and a continued trend toward outsourcing non-core functions among pharmaceutical manufacturers. Solutions providers, such as Two Labs, that act as strategic partners to pharmaceutical companies, and offer an exceptional customer value proposition are optimally positioned to benefit from these trends. We are thrilled to support Rich and his team as they continue to pursue their vision for growth.”

Rich Wartel, Founder and CEO of Two Labs, said, “A tremendous opportunity exists for Two Labs to further support our customers by enhancing our existing service capabilities, as well as strategically adding new solutions to the Two Labs portfolio. My team and I were in search of a partner that shared our vision for growth and could help us to achieve our goal of becoming the preeminent commercialization and lifecycle management partner for pharmaceutical manufacturers. We believe that we found such a partner in Excellere, which has substantial experience and resources within the outsourced pharma services industry and a proven track record of supporting management teams in growing healthcare businesses like ours.”

Together, Two Labs’ senior management and the Excellere team will seek to augment the company’s service portfolio through the development of additional value-added solutions, enhance the company’s proprietary technologies and tools, extend its geographic footprint, and expand its customer base through a targeted buy-and-build strategy.  Brad Cornell, Partner at Excellere Partners, said, “Two Labs is in a unique position to build upon its established brand reputation and recognized subject-matter- expertise to deliver more value to customers by adding complementary service capabilities and enhancing its existing solutions. We are excited to work with management to identify organic growth opportunities and strategic acquisitions that will allow Two Labs to solidify its position as the leading provider of commercial strategy and implementation services for pharmaceutical clients.”

About Two Labs
Two Labs is a leading provider of strategic consulting and implementation services to pharmaceutical companies, providing services across multiple stages of the drug development and commercialization process for a wide array of therapeutic areas. The company was founded in 2003 and is headquartered in Powell, Ohio.  For more information about Two Labs, please visit http://twolabsmarketing.com/.

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of capital across three funds, and specializes in partnering with entrepreneurs and management teams. The Firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth. Excellere’s investments are focused on differentiated and growth oriented companies positioned to benefit from industry consolidation and favorable macro-economic and

demographic trends. The Firm’s targeted industry sectors include: healthcare services and products; energy, power and infrastructure products and services; industrial technology, specialty chemicals and services; and business services. For more information about Excellere, please visit https://www.excellerepartners.com

+ Read Press Release
- Close Press Release

11.07.16
Excellere Partners Announces Strategic Investment in Riverside Radiology and Interventional Associates
Investment Represents Excellere’s 9th Platform in Excellere Capital Fund II, L.P.

Premier Imaging Ventures (“PIV”), the exclusive management services provider to Riverside Radiology and Interventional Associates (“Riverside” and combined with PIV, the “Company”) is pleased to announce the recent closing of a strategic growth partnership with Excellere Partners (“Excellere”).  Incorporated in 1980, Riverside is one of the ten largest radiology practices in the U.S. with 90 subspecialized physicians serving more than sixty facilities across Ohio and providing over 1.6 million annual interpretations.

Riverside has developed a unique, proprietary technology solution resulting in innovative workflow processes that drive exceptional clinical quality and efficiency and data analytics capabilities that are required to meet evolving reimbursement models.   The partnership with Excellere will provide the strategic and financial resources to enhance the Company’s business development capabilities and to pursue partnerships with other progressive radiology practices across the United States.  To this end, Riverside’s physician leaders, senior management and the Excellere team intend to implement a growth strategy comprised of foundational investments that further solidify Riverside and PIV’s scalable infrastructure; identified organic growth initiatives in existing and new markets; and complementary strategic partnerships across the U.S.

“We found an exceptional opportunity to partner with Excellere which has a proven track record of supporting physician practices in achieving transformative growth strategies.  The model that we have created maintains physician ownership and leadership of the clinical practice, provides compelling shareholder opportunities for younger physicians, and significant equity ownership for current and future physician-partners.  Our group was united in this decision and we believe that our radiology service model uniquely positions us to meet the evolving demands of our nation's healthcare delivery system as a radiologist-led enterprise,” said Dr. Mark Alfonso, Chief Medical Officer of the Company.

Marcia Flaherty, CEO of PIV, added “Riverside has a long track record of success by maintaining a focus on the best interests of the patients we serve with our hospital partners.  This progressive decision to align with a trusted, well respected, visionary investment partner demonstrates our enterprise-wide commitment to keeping the patient at the center of all we do.​   Our partnership with Excellere is consistent with our goals of remaining physician-owned and physician-led and offers an exciting future for our younger physician-partners.”

“We identified the radiology industry several years ago as a great segment of healthcare in which to execute Excellere’s value creation strategy.  We have dedicated significant resources to pursuing a radiology platform that had a patient-centric clinical model, differentiated technology and a passionate leadership team.  In Riverside, we have found an exceptional partner,” said David Kessenich, an Excellere Co-Founder and Managing Partner.

“Excellere is excited to be partnering with the physicians and management team of Riverside and PIV.  Their commitment to exceptional patient care, along with their facility partners and an innovative workflow technology solution, makes the Company the ideal platform from which to pursue a strategic growth strategy in the radiology services industry.  This partnership is perfectly aligned with our firm’s founding philosophy to invest in entrepreneurial healthcare businesses that are focused and dedicated to providing high quality patient care; while also creating value for the physicians, facilities and payers.  Together, Riverside and Excellere will further strengthen the Company’s presence, not only in Ohio, but in other attractive geographies by partnering with other leading radiology practices and expanding its service offerings.” Kessenich explained.

KeyBank Capital Markets served as the exclusive financial advisor to the board of directors of Riverside Radiology and Interventional Associates and Premier Imaging Ventures.

About Riverside Radiology
Riverside Radiology and Interventional Associates is a leading provider of professional radiology services to hospitals and other healthcare providers.  Formed in 1980, Riverside is one of the largest providers of radiology services in the U.S. and along with its affiliates, Premier Imaging Ventures, Lucid Radiology and Central Ohio PACS System, has developed industry-leading workflow and clinical processes and a broad spectrum of physician support services.  For more information about Riverside, please visit http://www.riversiderad.com

About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $1.36 billion of capital across three funds, and specializes in partnering with entrepreneurs and management teams.  The Firm employs a proven research-driven, top down investment strategy, and supports its entrepreneurs and management teams with a proprietary value creation process designed to enhance corporate and operational infrastructure for scalability and growth.  Excellere’s investments are focused on differentiated and growth oriented companies positioned to benefit from industry consolidation and favorable macro-economic and demographic trends.  The Firm’s targeted industry sectors include: healthcare services and products; energy, power and infrastructure products and services; industrial technology, specialty chemicals and services; and business services.  For more information about Excellere, please visit https://www.excellerepartners.com

+ Read Press Release
- Close Press Release